159 related articles for article (PubMed ID: 22184398)
1. Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer.
Sood AK; Coleman RL; Ellis LM
J Clin Oncol; 2012 Feb; 30(4):345-7. PubMed ID: 22184398
[No Abstract] [Full Text] [Related]
2. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
Cascone T; Heymach JV
J Clin Oncol; 2012 Feb; 30(4):441-4. PubMed ID: 22184396
[No Abstract] [Full Text] [Related]
3. Targeting the ANGPT-TIE2 pathway in malignancy.
Huang H; Bhat A; Woodnutt G; Lappe R
Nat Rev Cancer; 2010 Aug; 10(8):575-85. PubMed ID: 20651738
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer: TRINOVA-1, beyond VEGF inhibition.
Villanueva MT
Nat Rev Clin Oncol; 2014 Aug; 11(8):442. PubMed ID: 25001464
[No Abstract] [Full Text] [Related]
5. Trebananib: an alternative anti-angiogenic strategy.
Gourley C
Lancet Oncol; 2014 Jul; 15(8):776-7. PubMed ID: 24950984
[No Abstract] [Full Text] [Related]
6. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
7. Targeted anti-vascular therapies for ovarian cancer: current evidence.
Hall M; Gourley C; McNeish I; Ledermann J; Gore M; Jayson G; Perren T; Rustin G; Kaye S
Br J Cancer; 2013 Feb; 108(2):250-8. PubMed ID: 23385789
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Monk BJ; Poveda A; Vergote I; Raspagliesi F; Fujiwara K; Bae DS; Oaknin A; Ray-Coquard I; Provencher DM; Karlan BY; Lhommé C; Richardson G; Rincón DG; Coleman RL; Herzog TJ; Marth C; Brize A; Fabbro M; Redondo A; Bamias A; Tassoudji M; Navale L; Warner DJ; Oza AM
Lancet Oncol; 2014 Jul; 15(8):799-808. PubMed ID: 24950985
[TBL] [Abstract][Full Text] [Related]
9. Metronomic therapy: it makes sense and is patient friendly.
Kamen BA
J Pediatr Hematol Oncol; 2005 Nov; 27(11):571-2. PubMed ID: 16282885
[No Abstract] [Full Text] [Related]
10. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic agents in ovarian cancer: dawn of a new era?
Liu J; Matulonis UA
Curr Oncol Rep; 2011 Dec; 13(6):450-8. PubMed ID: 21993845
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
13. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage.
Koh YJ; Kim HZ; Hwang SI; Lee JE; Oh N; Jung K; Kim M; Kim KE; Kim H; Lim NK; Jeon CJ; Lee GM; Jeon BH; Nam DH; Sung HK; Nagy A; Yoo OJ; Koh GY
Cancer Cell; 2010 Aug; 18(2):171-84. PubMed ID: 20708158
[TBL] [Abstract][Full Text] [Related]
14. Gynaecological cancer: AURELIA--ovarian combination.
Errico A
Nat Rev Clin Oncol; 2014 May; 11(5):242. PubMed ID: 24687034
[No Abstract] [Full Text] [Related]
15. Chemotherapy for recurrent ovarian cancer.
Kaye SB
Lancet; 2003 Jun; 361(9375):2094-5. PubMed ID: 12826426
[No Abstract] [Full Text] [Related]
16. Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.
Liu JF; Cannistra SA
J Clin Oncol; 2014 May; 32(13):1287-9. PubMed ID: 24637996
[No Abstract] [Full Text] [Related]
17. Combination of bevacizumab and chemotherapy for platinum-resistant recurrent ovarian cancer: some observations about the AURELIA trial.
Tomao F; Tomao S; Benedetti Panici P
J Clin Oncol; 2014 Nov; 32(31):3580. PubMed ID: 25185105
[No Abstract] [Full Text] [Related]
18. Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice.
Tuppurainen L; Sallinen H; Karvonen A; Valkonen E; Laakso H; Liimatainen T; Hytönen E; Hämäläinen K; Kosma VM; Anttila M; Ylä-Herttuala S
Int J Gynecol Cancer; 2017 Jun; 27(5):879-886. PubMed ID: 28498260
[TBL] [Abstract][Full Text] [Related]
19. How to sequence treatment in relapsed ovarian cancer.
Pignata S; Cecere SC
Future Oncol; 2021 Jan; 17(3s):1-8. PubMed ID: 33355013
[TBL] [Abstract][Full Text] [Related]
20. [Standard of chemotherapy in ovarian cancer].
Pfleiderer A; Meerpohl HG
Chirurg; 1994 Jan; 65(1):18-22. PubMed ID: 8149794
[No Abstract] [Full Text] [Related]
[Next] [New Search]
